This product has not been evaluated for the diagnosis, treatment, cure, or prevention of any disease
In addition to obesity, beneficiaries were coded with overweight if the following ICD-10 codes were identified in the claims with the same requirements as the CCW OBESITY flag: E66.3, Z68.25, Z68.26, Z68.27, Z68.28
Despite the extensive studies in the past decades, the fundamental mechanism responsible for the development and progression of AD has not yet been fully elucidated
Monitoring your health while using a GLP-1 receptor agonist is important, and certain symptoms or situations, such as the ones below, should prompt a consultation with a doctor: New or worsening gastrointestinal symptoms, such as persistent nausea, vomiting, diarrhoea, or signs of dehydration 7 , 27
While appreciation has taken center stage, some analysts have also questioned her association with weight loss medication Zepbound
In the STEP Phase 3 studies , weight loss with Wegovy was assessed up to 68 weeks (104 weeks in STEP 5) in approximately 4,500 adults without type 2 diabetes taking Wegovy or an inactive placebo